TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23325481
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice daily for 3.5 days
Study: 23325481
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride XR 60 mg once daily for 10 days
Study: 23325481
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride XR and metformin coadministration
Study: 19858754
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (electrotherapies and lumbar strengthening exercises)
Study: 15205566
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day vaginal micronized progesterone (group I)
Study: 15205566
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 100 microg/day + 600 mg/day vaginal micronized progesterone (group II)
Study: 11502994
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day) for 8 weeks
Study: 11502994
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg/day) for 8 weeks
Study: 9113812
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg tid
Study: 9113812
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg tid
Study: 8256900
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (CS) therapy with methylprednisolone
Study: 3839972
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g sucralfate twice a day
Study: 3839972
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g sucralfate four times a day
Study: 22645114
Drug: Endoscopic DCR
Normalized name: DCR-PHXC free acid
DrugBank: Nedosiran (DB17635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic DCR with mitomycin C (0.5 mg/mL applied for 10 minutes)
Study: 20728414
Drug: Acupuncture as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture as part of a Traditional Chinese Medicine (TCM) package
Study: 20728414
Drug: Acupuncture as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture as a monotherapy
Study: 7609169
Drug: Alarm therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm therapy
Study: 17919550
Drug: PHX1149 single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHX1149 single-dose (50 to 500 mg)
Study: 17919550
Drug: PHX1149 multiple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHX1149 multiple-dose (50 to 400 mg QD for 13 days)
Study: 16053461
Drug: Sertraline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (20 mg/day)
Study: 16053461
Drug: Alprazolam (1-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1-1.5 mg/day)
Study: 12352513
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula with a protein/energy ratio of 2.2 g/100 kcal
Study: 12352513
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with a protein/energy ratio of 1.8 g/100 kcal
Study: 10597955
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplement 1.0 mg
Study: 10597955
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplement 2.5 mg
Study: 10597956
Drug: No folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No folic acid supplement
Study: 9798800
Drug: UDCA 10
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 10 mg/kg/day
Study: 10075964
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of simvastatin and UDCA
Study: 1992600
Drug: nilutamide (Anandron),
Approvals — FDA: no, EMA: no, PMDA: no
Description: nilutamide (Anandron), 100 mg t.i.d. with orchiectomy
Study: 18414360
Drug: Propofol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.4 mg/kg)
Study: 25574984
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (3 ml)
Study: 22491350
Drug: Acute alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute alcohol administration (0.8 g/kg)
Study: 20389159
Drug: Sirolimus, low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus, low-dose tacrolimus, and steroids (Group A)
Study: 20389159
Drug: Sirolimus, mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus, mycophenolate mofetil, and steroids (Group B)
Study: 12457449
Drug: Dual-fortified salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-fortified salt (iodine 25 microg/g salt and iron 1 mg/g salt)
Study: 12457449
Drug: Iodized salt
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized salt (25 microg iodine/g salt)
Study: 8596499
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise training (RE) + recombinant human growth hormone (rhGH)
Study: 8596499
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise training (RE) or hormone treatment
Study: 1749302
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with folinic acid, 5-Fluorouracil (FU) and mitomycin C (MMC)
Study: 7044606
Drug: Control (Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Medical treatment)
Study: 30817778
Drug: All biomarkers
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All biomarkers measured at Day 1 (except urinary L-FABP)
Study: 26341963
Drug: Botanicals with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botanicals with anticonvulsant properties
Study: 21308609
Drug: Hypertonic sodium
Normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic sodium chloride solution (3% NaCl)
Study: 21308609
Drug: Isotonic salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic salt solution (0.9% NaCl)
Study: 19084860
Drug: Combined perianal‐intrarectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined perianal‐intrarectal lidocaine‐prilocaine cream and periprostatic nerve block (group 1)
Study: 19084860
Drug: Perianal‐intrarectal lidocaine‐prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perianal‐intrarectal lidocaine‐prilocaine cream alone (group 2)
Study: 17463297
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium beverage (164 mmol Na(+)/l)
Study: 17463297
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium beverage (10 mmol Na(+)/l)
Study: 28860046
Drug: IVB (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVB (2.5 mg/0.1 mL) administered 5-10 days before PPV (Group B)
Study: 28860046
Drug: IVB (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVB (2.5 mg/0.1 mL) administered 1-3 days before PPV (Group A)
Study: 17535636
Drug: Nutritional remedy
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional remedy with the dipeptide of glutamine and alanine (Group G)
Study: 17535636
Drug: Routine nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine nutritional therapy only (Group C)
Study: 15070913
Drug: 20K-hGH 0.006
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20K-hGH 0.006 mg/kg.d
Study: 15070913
Drug: 20K-hGH 0.012
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20K-hGH 0.012 mg/kg.d
Study: 15070913
Drug: 20K-hGH 0.024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20K-hGH 0.024 mg/kg.d
Study: 9428488
Drug: Breast-conserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving therapy (BCT) including excisional biopsy and postoperative external beam irradiation (45-50 Gy to the whole breast and a boost to the tumor bed to at least 60 Gy)
Study: 28158558
Drug: Step Care
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step Care intervention (single counseling session, nicotine patch for six weeks, telephonic contact)
Study: 28158558
Drug: Recycle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recycle intervention (one session of health behavior counseling, nicotine patch for six weeks, telephone call at each step)
Study: 21334613
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant FSH (50‐150 IU/d) plus ganirelix (0.25 mg/d)
Study: 14755132
Drug: lamotrigine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamotrigine (300 mg per os)
Study: 11389707
Drug: lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin 20 mg/d
Study: 9268795
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (5 mg)
Study: 9268795
Drug: Bupivacaine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (50 mg)
Study: 9268795
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine sulfate and bupivacaine
Study: 8299668
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (F)
Study: 8299668
Drug: Inhaled bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled bumetanide (B)
Study: 3202502
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (S)
Study: 31641769
Drug: Bedtime hypertension
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime hypertension treatment (n=9552)
Study: 31641769
Drug: Upon awakening
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upon awakening hypertension treatment (n=9532)
Study: 22643725
Drug: Interferential light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential light therapy with two independent cluster probes (n = 15)
Study: 22643725
Drug: Conventional light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional light therapy with one active probe (n = 15)
Study: 10639529
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg mexiletine
Study: 8628358
Drug: C1 inhibitor
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1 inhibitor (25 plasma units per kilogram of body weight)
Study: 8628358
Drug: C1 inhibitor
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1 inhibitor (25 plasma units per kilogram)
Study: 1324529
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) products
Study: 26558434
Drug: Amlodipine oral
Normalized name: amlodipine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine oral solution 0.5 mg/mL
Study: 26558434
Drug: Norvasc® 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norvasc® 5 mg tablets
Study: 22127561
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium bicarbonate infusion
Study: 22127561
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (isotonic saline)
Study: 22127561
Drug: Both trials
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both trials (Isotonic sodium bicarbonate infusion and Placebo infusion)
Study: 15827359
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of expert and self videotape feedback
Study: 8550362
Drug: Sumatriptan 100
Normalized name: sumatriptan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 100 mg tid for 7 days
Study: 339659
Drug: Clonidine 75
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 75 microgram twice daily
Study: 31650795
Drug: β-caryophyllene (126
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-caryophyllene (126 mg/day)
Study: 16854755
Drug: Zinc/clindamycin gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc/clindamycin gel (Zindaclin 1%)
Study: 16854755
Drug: Clindamycin lotion
Normalized name: clindamycin Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin lotion (Dalacin T)
Study: 11170778
Drug: Nutrison Packs
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrison Packs (2 x 1000 mL triple foil laminated pouches)
Study: 11170778
Drug: Ross Ready‐to‐Hang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ross Ready‐to‐Hang containers (2 x 1000 mL rigid plastic bottles)
Study: 8143833
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 4 mg, administered four times daily for patients on inhaled corticosteroids and twice daily for those on bronchodilator alone.
Study: 31134640
Drug: HMB complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB complex (3 g HMB, 14 g arginine, and 14 g glutamine daily)
Study: 31134640
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard nutrition therapy)
Study: 31134640
Drug: HMB complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB complex (in subgroup with sequential organ failure assessment scores <10)
Study: 31134640
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (in subgroup with sequential organ failure assessment scores <10)
Study: 26317618
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading and 10 mg maintenance dose)
Study: 26317618
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg reloading and 150 mg maintenance dose)
Study: 26267731
Drug: Adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (80 mg at week 0, then 40 mg every other week starting at week 1)
Study: 10988047
Drug: USPIO ferumoxtran-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: USPIO ferumoxtran-10 at a dose of 0.8 mg Fe/kg
Study: 10988047
Drug: USPIO ferumoxtran-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: USPIO ferumoxtran-10 at a dose of 1.1 mg Fe/kg
Study: 10988047
Drug: USPIO ferumoxtran-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: USPIO ferumoxtran-10 at a dose of 1.7 mg Fe/kg
Study: 23800977
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg/day
Study: 1826213
Drug: atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 100 mg/day
Study: 30701811
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with chronic hepatitis C with insulin resistance (HOMA index ≥2.77)
Study: 30701811
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with chronic hepatitis C without insulin resistance (HOMA index <2.77)
Study: 23280545
Drug: Saffron (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (30 mg/daily)
Study: 20625290
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor blockers (MRBs) such as spironolactone or eplerenone, low doses added onto an angiotensin-converting enzyme inhibitor-based regimen
Study: 20625290
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor blockers (MRBs)
Study: 16149294
Drug: Sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2 g three times daily during radiotherapy
Study: 16149294
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets during radiotherapy
Study: 8521122
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of F‐CHX‐Zn
Study: 2140488
Drug: Alfentanil continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil continuous infusion
Study: 18978503
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 2 g/d
Study: 18978503
Drug: Methadone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone + Acetyl-L-carnitine (ALC) in morphine-tolerant mice
Study: 9046194
Drug: Tannic acid
Normalized name: Tannic Acid
DrugBank: Tannic acid (DB09372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tannic acid (20%) lotion
Study: 1326339
Drug: ORG 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 2766 (20 mg per day during 4 weeks)
Study: 4015388
Drug: Primary closure
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary closure with subcutaneous drains
Study: 26988951
Drug: Continued warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued warfarin during surgery
Study: 26988951
Drug: Empiric antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotics upon development of hematoma
Study: 18396717
Drug: Autologous free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous free fat particle injection
Study: 18396717
Drug: Autologous free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous free fat particle injection combined with bFGF (4,200 IU/10 mL)
Study: 12878632
Drug: Alizapride 50
Normalized name: alizapride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride 50 mg
Study: 26758574
Drug: Saffron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (1 g)
Study: 26758574
Drug: Ginger (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (3 g)
Study: 26758574
Drug: Cinnamon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (3 g)
Study: 26758574
Drug: Cardamom (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardamom (3 g)
Study: 18327970
Drug: Wand local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wand local anesthetic system at a deposition rate of 45 seconds (fast injection)
Study: 18327970
Drug: Wand local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wand local anesthetic system at a deposition rate of 4 minutes and 45 seconds (slow injection)
Study: 18327970
Drug: Conventional syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional syringe injection at a deposition rate of 4 minutes and 45 seconds (slow injection)
Study: 15912483
Drug: Alcohol (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (average 40 mg and 28 mg alcohol/100 ml blood at the beginning and end of drive)
Study: 1908498
Drug: Initial full
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial full dose of praziquantel followed by suppressive doses
Study: 1908498
Drug: Initial loading
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial loading praziquantel dose followed by suppressive dose at monthly intervals
Study: 1908498
Drug: Oral metrifonate
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metrifonate therapeutic course followed by prophylactic course monthly
Study: 1908498
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of oral praziquantel
Study: 1908498
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose of praziquantel orally every month
Study: 1908498
Drug: Oral metrifonate
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metrifonate curative course every 2 weeks for 3 doses every 6 months
Study: 1908498
Drug: Oral monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral monthly praziquantel prophylactic dose
Study: 1908498
Drug: Praziquantel prophylactic
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel prophylactic doses at 3-monthly intervals
Study: 1908498
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo in the form of vitamin B complex tablets at 3-monthly intervals
Study: 1908498
Drug: Oral monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral monthly therapeutic dose of metrifonate
Study: 1908498
Drug: Oral monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral monthly prophylactic doses of praziquantel
Study: 1908498
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo in the form of 2 vitamin B-complex tablets monthly
Study: 30413359
Drug: Tablet-based interactive
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based interactive distraction (TBID; 1 minute preseparation)
Study: 30413359
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (15 to 45 minutes of preseparation)